Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329919 | 0.91 | ESR2 (0.48) | MAPTESR2MKNK1ADORA1NR1H2 | |
| SCHEMBL9951760 | 0.91 | ESR2 (0.48) | MAPTESR2MKNK1ADORA1NR1H2 | |
| SCHEMBL31548527 | 0.91 | ESR2 (0.48) | MAPTESR2MKNK1ADORA1NR1H2 | |
| SCHEMBL1013846 | 0.85 | POLB (0.48) | POLBMAPTESR2GPR119MAP4K4 | |
| SCHEMBL22715947 | 0.83 | ESR2 (0.43) | MAPTESR2GPR119MAP4K4MKNK1 | |
| SCHEMBL12333398 | 0.80 | MAPT (0.47) | MAPTESR2GPR119MKNK1ADORA1 | |
| SCHEMBL1330087 | 0.79 | ESR2 (0.47) | POLBMAPTESR2MKNK1ADORA1 | |
| SCHEMBL3824436 | 0.78 | P2RX7 (0.35) | — | |
| SCHEMBL21003227 | 0.77 | ADORA1 (0.43) | MAPTESR2MKNK1ADORA1NR1H2 | |
| SCHEMBL12305710 | 0.77 | MAPT (0.45) | MAPTESR2MAP4K4MKNK1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568954-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024032561-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE (CDK) 12 AND/OR CDK13 AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-02-15 | — | — | WO | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738649-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-9422293-B2 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-08-23 | — | — | US | disclosed |
| US-7795262-B2 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2024368-A2 | 6,7,8,9-TETRAHYDRO-5H-PYRIMIDO[4,5-D]AZEPIN-4-YL]-AMINE DERIVATIVES AS MODULATORS OF TRPV1 FOR THE TREATMENT OF PAIN | Janssen Pharmaceutica, N.V. (BE) | 2009-02-18 | — | — | EP | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109355-A2 | 6,7,8, 9 -TETRAHYDRO- 5H- PYRIMIDO [4, 5-D] AZEPIN-4-YL] -AMINE DERIVATIVES AS MODULATORS OF TRPVL FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318942-A1 | TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1 | TRPV1, TRPA1, TRPV2 | POLB 4691/4885MAPT 873/4885ESR2 2033/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | POLB 3403/4885MAPT 979/4885ESR2 1905/4885 |
| US-20070225275-A1 | Tetrahydro-pyrimidoazepines as modulators of TRPV1 | TRPV1, TRPA1, TRPV2 | POLB 4710/4885MAPT 972/4885ESR2 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.